Genentech's Phase III IMvigor211 clinical trial did not meet its primary endpoint of overall survival.
The study evaluated TECENTRIQ (atezolizumab) in treating locally advanced or metastatic urothelial cancer (mUC) that had progressed during or after platinum-based chemotherapy treatments.
“While these results are not what we had expected, we believe that TECENTRIQ will continue to play an important role in the treatment of people with advanced bladder cancer,” Global Product Development Head and Chief Medical Officer Dr. Sandra Horning said. “We are committed to helping people with advanced bladder cancer and will discuss these data with health authorities.”
The study compared TECENTRIQ to chemotherapy drugs, docetaxel, paclitaxel or vinflunine, in 931 patients who had previously been treated with a platinum-based chemotherapy drug. The patients had already received at least one treatment regimen for mUC or developed mUC within one year of receiving chemotherapy.
Bladder cancer is the sixth-most common cancer, with more than 79,000 diagnoses anticipated in 2017. Urothelial cancers include the most common form, bladder cancer, and urethra, ureters and renal pelvis cancers. If bladder cancer is diagnosed early, the five-year survival rate is approximately 96 percent. If diagnosed at Stage III or IV, the five-year survival rate is 39 percent.
Alerts Sign-up